Peter G. Rose
ORCID: 0000-0003-2676-0166
· 5 papers in corpus
nonrandomized-trial
2018
OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear …
other
2017
PURPOSE: We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). METHODS: We reviewed data from FIGO stage I-IV epithelial ovarian cancer patients who parti…
other
2016
read with interest the special article by Howe et al. (1). A 14.5 % annual in-crease in peritoneal cancer was observed from 1992 through 1998. Peritoneal can-cer was first described by Smerdlow (2) in 1959 and has since been referred to by …
case-report
2000
A 41-year-old woman with a history of endometriosis had breast carcinoma diagnosed and treated with tamoxifen. A pelvic mass was subsequently diagnosed and observed on serial ultrasonographic examinations to increase in size. At surgery ext…
case-report
1998
BACKGROUND: In patients with endometrial carcinoma, the use of hysteroscopy may result in malignant peritoneal cytology. The significance of these mechanically disseminated malignant cells is uncertain. CASE: Disseminated endometrial carci…